IMG Biosciences enacts massive lay-offs after Phase I trial failure
18 hours ago · California-based biotech, IGM Biosciences, has put a halt to the development of two of its autoimmune disease therapies, imvotamab and IGM-2644, after Phase I trials saw disappointing results ...
IGM’s autoimmune pivot backfires as top drug disappoints in testing
2 days ago · IGM Biosciences will scrap its top two drugs and lay off nearly three-quarters of its workforce after reporting study results that fell short of the company’s expectations. In an announcement Thursday , IGM said it halted development of experimental therapies known as imvotamab and IGM-2644 that were being tested in autoimmune conditions.
IGM Biosciences Shares Drop 68% as Company Halts Key …
14 hours ago · IGM is reducing its staff by around 73% in order to save money amid a continuous assessment of strategic options. The corporation reported unaudited cash and assets of $183.8 million as of Dec. 31 ...
IGM Biosciences Halts Antibody Therapies, Cuts Workforce
6 hours ago · IGM Biosciences ( ) just unveiled an update. IGM Biosciences announced a strategic update to halt the development of two antibody therapies, imvotamab and IGM-2644, for autoimmune diseases due to ...
IGM Biosciences Halts Development Of Imvotamab, IGM-2644; …
1 day ago · (RTTNews) - Biotechnology company IGM Biosciences, Inc. (IGMS), Thursday announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell ...
IGM Biosciences Provides Strategic Update on Autoimmunity …
1 day ago · – Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited ...
IGM Biosciences to Halt Development of Imvotamab, Cut 73% of …
2 days ago · By Chris Wack. IGM Biosciences has decided to halt development of imvotamab and IGM-2644, two IgM-based bispecific antibody T cell engagers for autoimmune diseases, and cut its staff by 73%.
Top 1% Biotech, IGM Biosciences, Plummets On Scrapped Drug, …
Oct 1, 2024 · IGM Biosciences (IGMS) is developing imvotamab as a treatment for rheumatoid arthritis and systemic lupus erythematosus. In the shift, IGM is winding down efforts to develop aplitabart, a...
IGM Biosciences Lays Off 73% of Staff, Shrinks Pipeline
16 hours ago · IGM Biosciences is cutting 73% of its workforce and stopping development of two autoimmune drug candidates, the biotech announced Jan. 9. Following the news, BMO Capital Markets downgraded the Mountain View, California–based company’s shares from …
IGM Biosciences Halts Development of Two Investigational …
18 hours ago · IGM Biosciences announced they are halting the development of two investigational drugs for autoimmune and inflammatory diseases, imvotamab (an IgM-based CD20 X CD3 bispecific antibody T cell engager) and IGM-2644 (an IgM-based CD38 X CD3 bispecific antibody T cell engager).. Interim data from the Phase 1b studies of imvotamab for people with rheumatoid arthritis and systemic lupus ...
- Some results have been removed